Peer-reviewed veterinary case report
Safe vaccine protects dogs against distemper and parvovirus
By Hu, Ying et al.·Published in Veterinary microbiology·2026·Huazhong Agricultural University, China·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: A replication-defective bivalent adenovirus-vectored vaccine provides robust and durable protection against both canine distemper virus and canine parvovirus.
- Species:
- dog
Plain-English summary
A new vaccine for dogs has been developed to protect against two serious diseases: canine distemper virus (CDV) and canine parvovirus (CPV). This vaccine, called Ad5-(VP2+H), is designed to be safer than traditional vaccines, which can sometimes revert to a harmful form. In tests, this new vaccine produced a strong and lasting immune response in dogs, showing it could effectively prevent both diseases without the risks associated with live vaccines. This could be a great option for dog owners looking to keep their pets safe from these contagious and potentially fatal viruses.
People also search for: dog distemper vaccine safety · canine parvovirus prevention · new dog vaccines 2023
Abstract
Canine distemper virus (CDV) and canine parvovirus (CPV) are highly contagious and often fatal pathogens in dogs. Current live-attenuated vaccines, while effective, carry the risk of virulence reversion. This study aimed to develop a safer, replication-defective bivalent vaccine using an adenovirus vector to simultaneously protect against both CDV and CPV. The recombinant vaccine, designated Ad5-(VP2 +H), was engineered to coexpress the CDV hemagglutinin (H) protein (CDV-H) and the CPV Viral Protein 2 (CPV-VP2). Its immunogenicity and protective efficacy were evaluated in mouse and canine models. The results demonstrated that Ad5-(VP2 +H) elicited a potent and durable antigen-specific immune response. Furthermore, compared with a commercially available live attenuated vaccine, the Ad5-(VP2 +H) candidate exhibited a superior safety profile. In conclusion, the adenovirus-vectored Ad5-(VP2 +H) vaccine is a promising and safer alternative for the simultaneous prevention of CDV and CPV in dogs. This approach addresses the key limitation of traditional live-attenuated vaccines by eliminating the risk of virulence reversion while providing effective immunity.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/41655498/